Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

Not Applicable

Recruiting

• Conditions: Cirrhosis; HCC - Hepatocellular Carcinoma; Portal Vein Thrombosis
• Interventions: Drug: Enoxaparin, warfarrin, or apixaban

• Registration Number: NCT07132515
• Lead Sponsor: Mansoura University

Brief Summary

We will give an anticoagulant against portal vein thrombosis, and watch for the results.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-08-15
• Status Verified: 2025-08
• Primary Completion: 2025-08
• Study Completion: 2025-08-01
• Study First Submitted: 2025-08-10
• Study First Submitted QC: 2025-08-17
• Last Update Submitted: 2025-08-17
• Study First Posted: 2025-08-20
• Last Update Posted: 2025-08-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Portal vein thrombosis, Cirrhosis, With or without HCC, Child A & B

Exclusion Criteria

• Platelets<10000, Createnine >1.9, Budd ciarri, Uncontrolled active bleeding

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Anticoagulant in cirrhosis with HCC	Enoxaparin, warfarrin, or apixaban	HCC patient on anticogulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)
Anticoagulant in Cirrhosis without HCC	Enoxaparin, warfarrin, or apixaban	Benign thrombus in cirrhotic patient on anticoagulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)

Primary Outcome Measures

Name	Time	Method
Portal vein thrombosis	6 months	determine if thrombus resolved or not on anticcoagulant by triphasic CT

Trial Locations

Locations (1)

Mansoura University Hospitals; 🇪🇬 Mansoura, Dakahlia, Egypt